As-needed ruxolitinib cream held atopic dermatitis control in children for a year

Design

44-week open-label long-term safety extension of a phase 3 randomised trial (TRuE-AD3)

Population

282 children aged 2–11 with mild-to-moderate atopic dermatitis

Primary outcome

Long-term safety and disease control with as-needed use

Effect

Application-site reactions 1.1%; IGA 0/1 at week 52 in 79.5% (0.75%) and 72.3% (1.5%)

This extension of a phase 3 trial followed 282 children aged 2 to 11 with mild-to-moderate atopic dermatitis who had completed eight weeks of randomised treatment. For a further 44 weeks they applied ruxolitinib cream, a topical JAK1/JAK2 inhibitor, at 0.75% or 1.5%, twice daily but only when needed.

No new safety signals appeared. Application-site reactions occurred in about 1%, and there were no serious treatment-related adverse events. Among children randomised to the cream from the start, about 80% on 0.75% and 72% on 1.5% had clear or almost clear skin at week 52, with about 2% of body surface affected.

The extension had no vehicle arm, so some of the control could reflect the natural waxing and waning of eczema or good adherence to emollients. And one year is short for judging a drug class whose oral forms carry boxed warnings.

For now, this supports topical JAK inhibition as a steroid-sparing option for limited eczema in young children, used intermittently on affected areas. Availability and cost in India are uncertain, and topical steroids and calcineurin inhibitors remain the established options.

• Consider ruxolitinib cream as a steroid-sparing option for limited eczema in children over 2, where available.
• Apply it to affected areas as needed, not continuously, as in this study.
• Keep total treated area limited, as in the trial population.
• Continue emollients and trigger avoidance alongside any active treatment.
• Topical steroids and calcineurin inhibitors remain standard first-line choices.

Why it matters

It gives clinicians a year of paediatric data for a non-steroid cream in the age group where steroid worry runs highest.

Don't overread it

The 44-week extension had no control arm and is too short to settle long-term safety.

The statistics, in plain English

The 72–80% figures describe children who stayed in the study on active cream, with no comparison group in this phase. Without a vehicle arm, we cannot say how much of the control is due to the cream itself.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.